Here's What Boosted Verona Pharma plc (VRNA) Share Price by 49%

TimesSquare Capital Management, an equity investment management company, released its “U.S. Small Cap Growth Strategy” second-quarter 2025 investor letter. A copy of the letter can be downloaded here. During the quarter, the fund returned 11.28% (gross) and 11.02% (net), compared to the Russell 2000 Growth Index by 11.97%. Equities posted double-digit returns in the second quarter as global economic activity measures lifted. In addition, please check the fund’s top five holdings to know its best picks in 2025.

In its second-quarter 2025 investor letter, TimesSquare Capital Small Cap Growth Strategy highlighted stocks such asVerona Pharma plc (NASDAQ:VRNA). Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company. The one-month return of Verona Pharma plc (NASDAQ:VRNA) was 1.07%, and its shares gained 257.29% of their value over the last 52 weeks. On September 11, 2025, Verona Pharma plc (NASDAQ:VRNA) stock closed at $106.40 per share, with a market capitalization of $9.042 billion.

TimesSquare Capital U.S. Focus Growth Strategy stated the following regarding Verona Pharma plc (NASDAQ:VRNA) in its second quarter 2025 investor letter:

"Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that deserve premium pricing, or specialized service providers. Verona Pharma plc (NASDAQ:VRNA) is a biopharmaceutical company focused on developing therapies to treat respiratory diseases. Ohtuvayre, a prescription medication used to treat chronic obstructive pulmonary disease, generated higher sales and led to a solid first quarter. Thus far, the drug launch is exceeding expectations. That served to boost the share price by 49%."

Verona Pharma plc (NASDAQ:VRNA) is not on our list of 30 Most Popular Stocks Among Hedge Funds. As per our database, 59 hedge fund portfolios held Verona Pharma plc (NASDAQ:VRNA) at the end of the second quarter, which was 51 in the previous quarter. While we acknowledge the potential of Verona Pharma plc (NASDAQ:VRNA) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

In another article, we covered Verona Pharma plc (NASDAQ:VRNA) and shared a list of the best mid cap growth stocks to buy according to hedge funds. In addition, please check out our hedge fund investor letters Q2 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.